Electra Therapeutics has raised $350.0M to push its pipeline of immunology and cancer drugs forward. The clinical-stage biotech is developing therapies that target signal regulatory proteins, or SIRP, a family of molecules that help regulate immune cell activity.
The company hasn't disclosed the round type or its investors.















